Imugene Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Leslie Chong

4.83yrs

Tenure

AU$1,153,580

Compensation

Ms. Leslie Chong serves as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21, 2016. Ms. Chon...


CEO Compensation Analysis

How has Leslie Chong's remuneration changed compared to Imugene's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022AU$1mAU$600k

-AU$38m

Mar 31 2022n/an/a

-AU$33m

Dec 31 2021n/an/a

-AU$27m

Sep 30 2021n/an/a

-AU$23m

Jun 30 2021AU$789kAU$408k

-AU$18m

Mar 31 2021n/an/a

-AU$15m

Dec 31 2020n/an/a

-AU$12m

Sep 30 2020n/an/a

-AU$11m

Jun 30 2020AU$733kAU$375k

-AU$11m

Mar 31 2020n/an/a

-AU$10m

Dec 31 2019n/an/a

-AU$9m

Sep 30 2019n/an/a

-AU$8m

Jun 30 2019AU$777kAU$350k

-AU$8m

Mar 31 2019n/an/a

-AU$7m

Dec 31 2018n/an/a

-AU$6m

Sep 30 2018n/an/a

-AU$5m

Jun 30 2018AU$403kAU$300k

-AU$4m

Mar 31 2018n/an/a

-AU$3m

Dec 31 2017n/an/a

-AU$3m

Sep 30 2017n/an/a

-AU$3m

Jun 30 2017AU$337kAU$290k

-AU$3m

Mar 31 2017n/an/a

-AU$3m

Dec 31 2016n/an/a

-AU$3m

Sep 30 2016n/an/a

-AU$3m

Jun 30 2016AU$323kAU$229k

-AU$3m

Compensation vs Market: Leslie's total compensation ($USD819.94K) is about average for companies of similar size in the Australian market ($USD1.06M).

Compensation vs Earnings: Leslie's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Paul Hopper
Executive Chairman10.25yrsAU$350.00k4.94%
A$ 46.0m
Leslie Chong
CEO, MD & Executive Director6.17yrsAU$1.15m1.2%
A$ 11.2m
Nicholas Ede
Chief Technology Officerno dataAU$490.82k0.29%
A$ 2.7m
Monil Shah
Chief Business Officer1.58yrsAU$1.62mno data
Michael Tonroe
Chief Financial Officer0.33yrno datano data
Ursula McCurry
Senior Vice President of Clinical Operations1yrno datano data
Giovanni Selvaggi
Chief Medical Officer0.25yrno datano data
Nathan Jong
Joint Company Secretary1.08yrsno datano data

1.0yrs

Average Tenure

Experienced Management: IMU's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Paul Hopper
Executive Chairman10.25yrsAU$350.00k4.94%
A$ 46.0m
Leslie Chong
CEO, MD & Executive Director4.83yrsAU$1.15m1.2%
A$ 11.2m
Charles Walker
Independent Non-Executive Director7.33yrsAU$83.41k0.35%
A$ 3.3m
Jens Eckstein
Independent Non-Executive Director3.67yrsAU$85.64k0.32%
A$ 3.0m
Yuman Fong
Chair of Oncolytic Virotherapy Scientific Advisory Board3.17yrsno data0%
A$ 0
Ursula Wiedermann
Member of Scientific Advisory Boardno datano datano data
Neil Segal
Member of Scientific Advisory Board8.75yrsno datano data
Josep Tabernero
Member of Scientific Advisory Board4.25yrsno datano data
Yelena Janjigian
Scientific Advisory Board Member6.75yrsno datano data
Peter Schmid
Member of Scientific Advisory Board5.08yrsno datano data
Tanios Bekaii-Saab
Member of Scientific Advisory Board4.33yrsno datano data
Pravin T. Kaumaya
Member of Scientific Advisory Board4.25yrsno datano data

4.8yrs

Average Tenure

Experienced Board: IMU's board of directors are considered experienced (4.8 years average tenure).